Recombinant leukocyte interferon treatment of chronic hepatitis B
Geoffrey Dusheiko, Adrian Dibisceglie, Sheila Bowyer, Evelyn Sachs, Marian Ritchie, Barry Schoub, Michael Kew – 1 July 1985 – We have investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg‐, HBeAg‐, hepatitis B virus DNA‐ and DNA polymerase‐positive carriers. α‐Interferon was administered for 9 weeks. Six of 14 treated carriers have a sustained loss of HBeAg, hepatitis B virus DNA and DNA polymerase. Four subsequently lost HBsAg (28.5%).